221 related articles for article (PubMed ID: 27388232)
1. Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression.
Ferroni P; Riondino S; Laudisi A; Portarena I; Formica V; Alessandroni J; D'Alessandro R; Orlandi A; Costarelli L; Cavaliere F; Guadagni F; Roselli M
Oncologist; 2016 Sep; 21(9):1041-9. PubMed ID: 27388232
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of glycated hemoglobin in colorectal cancer.
Ferroni P; Formica V; Della-Morte D; Lucchetti J; Spila A; D'Alessandro R; Riondino S; Guadagni F; Roselli M
World J Gastroenterol; 2016 Dec; 22(45):9984-9993. PubMed ID: 28018105
[TBL] [Abstract][Full Text] [Related]
3. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
4. 21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients.
Zhu Y; Wang T; Tong Y; Chen X; Shen K
Front Endocrinol (Lausanne); 2021; 12():725161. PubMed ID: 34456877
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
6. Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.
Goodwin PJ; Ennis M; Pritchard KI; Trudeau ME; Koo J; Taylor SK; Hood N
J Clin Oncol; 2012 Jan; 30(2):164-71. PubMed ID: 22162568
[TBL] [Abstract][Full Text] [Related]
7. Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.
Crispo A; Montella M; Buono G; Grimaldi M; D'Aiuto M; Capasso I; Esposito E; Amore A; Nocerino F; Augustin LS; Giudice A; Di Bonito M; Giuliano M; Forestieri V; De Laurentiis M; Rinaldo M; Ciliberto G; De Placido S; Arpino G
Curr Res Transl Med; 2016; 64(1):15-20. PubMed ID: 27140595
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
Muñoz-Montaño W; Cabrera-Galeana P; Alvarado-Miranda A; Villarreal-Garza C; Mohar A; Olvera A; Bargallo-Rocha E; Lara-Medina F; Arrieta O
Clin Breast Cancer; 2020 Aug; 20(4):307-316.e1. PubMed ID: 32305297
[TBL] [Abstract][Full Text] [Related]
9. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
10. The presentation of metabolic dysfunction and the relationship with energy output in breast cancer survivors: a cross-sectional study.
Guinan EM; Connolly EM; Kennedy MJ; Hussey J
Nutr J; 2013 Jul; 12():99. PubMed ID: 23855321
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
12. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
[TBL] [Abstract][Full Text] [Related]
14. Elevated fasting blood glucose is associated with increased risk of breast cancer: outcome of case-control study conducted in Karachi, Pakistan.
Haseen SD; Khanam A; Sultan N; Idrees F; Akhtar N; Imtiaz F
Asian Pac J Cancer Prev; 2015; 16(2):675-8. PubMed ID: 25684506
[TBL] [Abstract][Full Text] [Related]
15. Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer.
Bychkovsky BL; Guo H; Sutton J; Spring L; Faig J; Dagogo-Jack I; Battelli C; Houlihan MJ; Yeh TC; Come SE; Lin NU
Oncologist; 2016 Dec; 21(12):1495-1501. PubMed ID: 27551013
[TBL] [Abstract][Full Text] [Related]
16. Homeostasis model assessment to detect insulin resistance and identify patients at high risk of breast cancer development: National Cancer Institute of Naples experience.
Capasso I; Esposito E; Pentimalli F; Montella M; Crispo A; Maurea N; D'Aiuto M; Fucito A; Grimaldi M; Cavalcanti E; Esposito G; Brillante G; Lodato S; Pedicini T; D'Aiuto G; Ciliberto G; Giordano A
J Exp Clin Cancer Res; 2013 Mar; 32(1):14. PubMed ID: 23497533
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
18. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression.
Rodrigues Dos Santos C; Fonseca I; Dias S; Mendes de Almeida JC
BMC Cancer; 2014 Feb; 14():132. PubMed ID: 24571647
[TBL] [Abstract][Full Text] [Related]
19. Association Between Insulin Resistance and Luminal B Subtype Breast Cancer in Postmenopausal Women.
Nam S; Park S; Park HS; Kim S; Kim JY; Kim SI
Medicine (Baltimore); 2016 Mar; 95(9):e2825. PubMed ID: 26945364
[TBL] [Abstract][Full Text] [Related]
20. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
